Noga Therapeutics invites you to view, use and download a single copy of this Web site for your informational, non-commercial use. Except as otherwise provided on this page, no part of any content or software on this Web site may be copied, downloaded or stored in a retrieval system for any other purpose, nor may it be redistributed for any purpose, without the express written permission of Noga Therapeutics. You understand that Noga Therapeutics may discontinue, change, or restrict your use of this Web site for any reason without notice. By using this Web site, you represent that you are at least 18 years old and a U.S. resident.
ALL CONTENT ON THIS WEB SITE IS PROVIDED TO YOU ON AN “AS IS” “AS AVAILABLE” BASIS WITHOUT WARRANTY OF ANY KIND EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, AND NON-INFRINGEMENT. NOGA THERAPEUTICS MAKES NO WARRANTY AS TO THE ACCURACY, COMPLETENESS, CURRENCY, OR RELIABILITY OF ANY CONTENT AVAILABLE THROUGH THIS WEB SITE. YOU ARE RESPONSIBLE FOR VERIFYING ANY INFORMATION BEFORE RELYING ON IT. USE OF THE WEB SITE AND THE CONTENT AVAILABLE ON THE WEB SITE IS AT YOUR SOLE RISK. NOGA THERAPEUTICS MAKES NO REPRESENTATIONS OR WARRANTIES THAT USE OF THE WEB SITE WILL BE UNINTERRUPTED OR ERROR-FREE. YOU ARE RESPONSIBLE FOR TAKING ALL NECESSARY PRECAUTIONS TO ENSURE THAT ANY CONTENT YOU MAY OBTAIN FROM THE WEB SITE IS FREE OF VIRUSES. The above exclusions may not apply in jurisdictions that do not allow the exclusion of certain implied warranties.
YOUR USE OF THE WEB SITE OR ANY CONTENT ON THE WEB SITE IS AT YOUR OWN RISK. NOGA THERAPEUTICS SPECIFICALLY DISCLAIMS ANY LIABILITY, WHETHER BASED IN CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, FOR ANY DIRECT, INDIRECT, INCIDENTAL, CONSEQUENTIAL, OR SPECIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH ACCESS TO OR USE OF THE WEB SITE, EVEN IF NOGA THERAPEUTICS HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, INCLUDING BUT NOT LIMITED TO RELIANCE BY ANY PARTY ON ANY CONTENT OBTAINED THROUGH THE USE OF THE WEB SITE, OR THAT ARISES IN CONNECTION WITH MISTAKES OR OMISSIONS IN, OR DELAYS IN TRANSMISSION OF, INFORMATION TO OR FROM THE USER, INTERRUPTIONS IN TELECOMMUNICATIONS CONNECTIONS TO THE WEB SITE OR VIRUSES, WHETHER CAUSED IN WHOLE OR IN PART BY NEGLIGENCE, ACTS OF GOD, TELECOMMUNICATIONS FAILURE, THEFT OR DESTRUCTION OF, OR UNAUTHORIZED ACCESS TO THE WEB SITE, OR RELATED INFORMATION OR PROGRAMS.
Unauthorized use of any Noga Therapeutics trademark, service mark or logo may be a violation of federal and state trademark laws.
This Web site is protected by U.S. and foreign copyright laws. Except for your informational, personal, non-commercial use as authorized above, you may not modify, reproduce or distribute the design or layout of the Web site, or individual sections of the design or layout of the Web site or Noga Therapeutics logos without our written permission.
This Noga Therapeutics Web site may contain links to Web sites operated by other parties. The linked sites may not be under the control of Noga Therapeutics, and Noga Therapeutics is not responsible for the content available on any other Internet sites linked to the Web site. Such links do not imply Noga Therapeutics’s endorsement of material on any other site and Noga Therapeutics disclaims all liability with regard to your access to such linked Web sites. Noga Therapeutics provides links to other Internet sites as a convenience to users, and access to any other Internet sites linked to this Web site is at your own risk. Unless otherwise set forth in a written agreement between you and Noga Therapeutics, you must adhere to Noga Therapeutics’s linking policy as follows:
(i) any link to the Web site must be a text only link clearly marked “Noga Therapeutics Web site,”
(ii) the appearance, position and other aspects of the link may not be such as to damage or dilute the goodwill associated with Noga Therapeutics’s names and trademarks,
(iii) the link must “point” to the specific URL listed below:
and not to other pages within the Web site, (iv) the appearance, position and other attributes of the link may not create the false appearance that your organization or entity is sponsored by, affiliated with, or associated with Noga Therapeutics, (v) when selected by a user, the link must display the Web site on full-screen and not within a “frame” on the linking Web site, and (vi) Noga Therapeutics reserves the right to revoke its consent to the link at any time and in its sole discretion.
This Web site is operated by Noga Therapeutics from its offices in New York, USA. The law of the State of New York shall govern these terms and conditions, without reference to its choice of law rules. Noga Therapeutics makes no representation that the information in the Web site is appropriate or available for use in other locations, and access to the Noga Therapeutics Web site from territories where the content of the Noga Therapeutics Web site may be illegal is prohibited. Those who choose to access the Noga Therapeutics Web site from other locations do so on their own initiative and are responsible for compliance with applicable local laws.
Sefi is a 22-year entrepreneur who founded a Nasdaq-listed company. He has a proven track record of assembling exceptional teams and building technology ahead of its time.
Sefi founded HUB Cyber Security, which reached a peak market capitalization of $350 million. He also advised Bancor, which raised $153 million and reached a peak market capitalization of $800 million.
Currently Sefi is heading the investment team in a privately owned family office.
Sefi holds a B.Sc. in Business Administration and Economics from the University of Tel Aviv.
Mr. Adam Brian heads Lonza Personalized Medicine, which focuses on developing and bringing to market tools that enable research and development, scale out, and commercialization of patient scale cell therapies, with an emphasis on decentralized and point of care manufacturing. Mr. Brian is a results-oriented leader with extensive experience in the life science and medical device industries. Proven track record of increasing revenue, improving operations, and building and leading high-performing teams.
Dr. Eytan Abraham heads Resilience cell, gene and nucleic acids Franchises. Dr. Abraham holds a Ph.D. in developmental and molecular biology from the University of Maryland Biotechnology Institute, and a post-doctorate in cell-therapy and tissue engineering from the Harvard-MIT Biomedical Engineering Center and Harvard Medical School. Dr. Abraham is an experienced scientist and business leader with expertise in basic and applied biological and cell therapy R&D as well as in management, technology, and commercialization.
Anat Naschitz is a lifescience investor and entrepreneur, with 27 years of experience across biotech, pharma, digital health and medical devices.
Anat co-founded and co-led OrbiMed Israel, an Israel focused VC fund and part of the leading, $20bn global healthcare investment firm, and was previously with Apax, the €60bn private equity firm, where she started her investment career. Previously Anat was an Associate Partner with McKinsey in London, where she advised the world’s preeminent pharmaceutical companies on strategy, acquisitions and spinouts.
Throughout her career Anat has founded companies and nurtured them through success. Examples include 89bio (Nasdaq:ETNB), developing a likely best in class therapeutic for NASH, which she co-founded and spun out of Teva, taking it public on Nasdaq 18 months post creation, currently trading at $1bn; Sobi, which evolved out of a Pharmacia spinout and currently trading at $7.4bn; and many others.
Currently, Anat is co-founder and CEO of 9xchange, a biopharma marketplace, creating transparency and enabling the ecosystem to monetize pipelines and discover assets whose availability was unknown, through a seamless, initially anonymous, AI-driven process.
Anat earned her MBA at Insead in France and her LLB at Tel Aviv University.
Dr. Yeal Weiss is currently CEO of Mahzi Therapeutics, a company focused on the development of therapies for ultra-rare genetic neurodevelopmental disorders. Dr. Weiss completed her MD at Hadassah Medical School at the Hebrew University in Jerusalem and her PhD at the Weizmann Institute of Science in Rehovot, Israel. She has over 20 years of industry experience in medical/clinical and business development roles at Genzyme, Merck and Ultragenyx. Dr. Weiss is a member of the NIH driven Bespoke Gene Therapy (BCTG) consortium, ASGCT translational committee, N=1 collaborative and is a 2022 Termeer Fellow. Board member/advisor to ADNP and FOXG1 foundations.
Noam is a physician with 20 years of experience in the field of complementary medicine (Brighton University). He formerly headed the Chinese Medicine Unit at Sheba Hospital. Noam is the founder and CEO of the Association for Noga (Her Way), which develops advanced therapies for ultra-rare diseases.
Liron brings many years of experience in cell- and gene-therapy translation. Prior to joining NOGA Therapeutics, Liron headed the discovery and the early-phase development of oncology at Enlivex Therapeutics. Prior to that, Liron led the hemophilia A program (currently in phase III) at Spark Therapeutics, USA. Liron holds a PhD from and conducted postdoctoral research at the Technion.
Noam previously co-founded Emendo Biotherapeutics, a leading CRISPR company that was acquired by Anges, Japan, in 2020, for $295M. As an expert on intellectual property strategies at Ingenium IP, Noam advised dozens of biomed companies on building their IP-business strategy. Noam holds a PhD from the Weizmann Institute of Science in the field of DNA damage repair.